Residency · Residency · Medical Genetics Genomics

Autosomal Recessive Inheritance and Carrier Screening

Core Principles of Autosomal Recessive Inheritance

Definition and Characteristics

In autosomal recessive inheritance, both copies of a gene must carry pathogenic variants for disease to manifest, meaning the individual has biallelic variants. Affected individuals may be homozygous (carrying the same variant on both alleles) or compound heterozygous (carrying different variants on each allele). Carriers, who are heterozygous for a single pathogenic variant, are typically clinically unaffected, though they may occasionally have subtle biochemical findings. The characteristic pedigree pattern is horizontal: affected individuals appear in a single generation with unaffected parents. Males and females are equally affected. Affected individuals generally do not transmit disease to their children unless the other parent is also a carrier.

Recurrence Risk Calculations

When both parents are carriers, each pregnancy has a 25% chance of producing an affected child, a 50% chance of producing a carrier, and a 25% chance of producing a non-carrier. When an affected individual mates with a carrier, 50% of offspring are affected and 50% are carriers. When an affected individual mates with a non-carrier, all offspring are obligate carriers. When a carrier mates with a non-carrier, 50% of offspring are carriers and 50% are non-carriers, with no affected offspring expected. Modified Hardy-Weinberg calculations relate disease frequency to carrier frequency: if disease frequency equals q squared, carrier frequency equals 2pq, which is approximately 2q when q is small.

Distinguishing Compound Heterozygosity from Variants in Trans vs. Cis

Phasing is critical when two variants are identified in the same gene. Two variants on the same chromosome (in cis) represent only one mutant allele, not biallelic disease. The most reliable method for determining phase is parental testing. Alternative approaches include long-read sequencing and allele-specific PCR. Clinical laboratories should request parental samples whenever two variants are found in a recessive gene.

Consanguinity

Genetic Consequences

Consanguinity increases the probability that offspring are homozygous (autozygous) for alleles identical by descent. The coefficient of inbreeding (F) quantifies this probability: for first cousins, F equals 1/16; for second cousins, F equals 1/64; and for double first cousins, F equals 1/8. The inbreeding coefficient increases the likelihood of autosomal recessive disease by a factor of approximately (1 + 16F) for first-cousin matings. Offspring of consanguineous unions have increased rates of congenital anomalies, intellectual disability, and childhood mortality, with an empiric risk increase of about 2 to 3% above the baseline for first-cousin offspring.

Runs of Homozygosity (ROH)

SNP microarray and whole genome sequencing can detect long contiguous stretches of homozygosity. The total ROH burden correlates with the degree of parental relatedness. ROH analysis can identify candidate genomic regions for homozygous pathogenic variants in consanguineous families through a technique called homozygosity mapping. Incidental detection of unsuspected consanguinity or uniparental disomy on clinical microarray is also possible.

Founder Effects

A founder effect occurs when a pathogenic variant reaches high frequency in a specific population due to descent from a small number of founding individuals. The Ashkenazi Jewish population provides well-known examples, including Tay-Sachs disease (HEXA), Gaucher disease (GBA), cystic fibrosis (CFTR), Canavan disease (ASPA), and familial dysautonomia (ELP1). French Canadians have elevated frequencies of Tay-Sachs disease (with different variants from those in the Ashkenazi population) and tyrosinemia type I (FAH). The Finnish disease heritage encompasses approximately 40 enriched recessive conditions, including aspartylglucosaminuria, infantile neuronal ceroid lipofuscinosis, and nephronophthisis. Amish and Mennonite communities carry elevated frequencies of maple syrup urine disease (BCKDHA), glutaric aciduria type 1 (GCDH), and various community-specific conditions. The Sephardic Jewish population has elevated frequencies of familial Mediterranean fever (MEFV) and Wolman disease (LIPA).

Population-Based Carrier Screening

Evolution of Carrier Screening

Carrier screening has evolved through three eras. Targeted ethnic-based screening historically recommended screening for specific populations, such as Tay-Sachs screening in Ashkenazi Jewish individuals beginning in 1971, sickle cell screening in African Americans, and beta-thalassemia screening in Mediterranean populations. Panethnic screening emerged when ACOG and ACMG recommended cystic fibrosis screening for all couples regardless of ethnicity in 2001. Most recently, expanded carrier screening (ECS) enables simultaneous screening for dozens to hundreds of recessive and some X-linked conditions regardless of ethnicity.

Current Professional Society Positions

The ACMG, in its 2021 statement, recommends offering carrier screening for cystic fibrosis and SMA to all individuals of reproductive age and supports expanded carrier screening panels as an acceptable alternative. ACOG, in its 2023 guidance, supports offering ECS as an acceptable screening strategy while maintaining specific recommendations for CF, SMA, and hemoglobinopathies. The joint ACMG/ACOG position is that population-based screening should be offered to all individuals, ideally preconception.

Expanded Carrier Screening Panels

Panel Design Considerations

Gene and condition inclusion criteria typically require a carrier frequency of at least 1 in 200 in any population, a well-defined phenotype, significant health impact, and available prenatal or postnatal intervention. Debate continues around including conditions of variable severity (such as GJB2-related hearing loss or HFE-related hemochromatosis) and adult-onset conditions. Typical panels screen for 100 to over 400 conditions. Detection rates vary by ancestry due to differences in allele frequencies and coverage of population-specific variants.

Residual Risk

A negative screening result does not eliminate carrier risk. The residual risk depends on the detection rate for the specific gene and the individual's ethnic background. The detection rate represents the proportion of pathogenic alleles identified by the screening panel. Residual risk is the post-test carrier risk after a negative screen. For example, CF carrier screening in Northern European individuals detects approximately 90% of pathogenic alleles, yielding a residual carrier risk after a negative screen of approximately 1 in 240, compared to the pre-test risk of 1 in 25.

Methodology

Most expanded carrier screening platforms use next-generation sequencing with targeted gene panels. Some use genotyping arrays for common variants, which are lower cost but have lower detection rates in diverse populations. Important limitations include the inability of most panels to detect large deletions, complex rearrangements, or repeat expansions; supplementary assays are needed for FMR1 (fragile X), SMN1 (SMA copy number), and HBA1/2 (alpha-thalassemia deletions). Genes with pseudogenes or highly homologous sequences, such as SMN1/SMN2, GBA/GBAP1, and CYP21A2/CYP21A1P, require specialized analysis.

Couple-Based vs. Individual-Based Reporting

In the sequential (individual) model, one partner is screened first, and the second partner is screened only for conditions for which the first is a carrier. This approach reduces cost but may miss X-linked conditions and takes more time. In the simultaneous (couple-based) model, both partners are screened simultaneously and only at-risk couple results are reported. This is faster but raises ethical concerns about withholding individual carrier status. Most clinical laboratories report individual carrier results to each patient.

Genetic Counseling for Carrier Screening

Pre-Test Counseling

Pre-test counseling should discuss the purpose, scope, and limitations of screening. It is important to explain the difference between carrier status and being affected, and to address the possibility of detecting carrier status for conditions not previously considered. The concept of residual risk should be reviewed: a negative result significantly reduces but does not eliminate carrier risk. Informed consent should include the option to decline screening.

Post-Test Counseling for Carrier Couples

When both partners are carriers for the same autosomal recessive condition, the 25% recurrence risk per pregnancy should be reviewed along with disease natural history, treatment options, and prognosis for the specific condition. Reproductive options include prenatal diagnosis (CVS or amniocentesis), PGT-M with IVF, gamete donation, adoption, or accepting the risk. Carrier status for X-linked conditions is relevant for female carriers even without a carrier partner. Cascade testing of at-risk relatives should be encouraged.

Special Considerations

Pseudodeficiency alleles can cause false-positive results on enzyme-based carrier screening. Some enzymatic assays yield low activity in carriers of pseudodeficiency alleles who are not true disease carriers, as occurs with HEXA and ARSA. Molecular testing resolves this discrepancy. Complex alleles, in which multiple variants exist on the same allele in cis, can alter disease severity, as seen with CFTR complex alleles. Ideally, screening is performed preconception; prenatal screening is acceptable but limits the available options. Discordant results between partners may require additional confirmatory testing or genetic counseling.

<image>A pedigree diagram illustrating autosomal recessive inheritance in a consanguineous family. Two unaffected first-cousin parents (double horizontal line connecting them) are shown with carrier status indicated by half-filled symbols. Their offspring include one affected child (fully filled), two carriers (half-filled), and one non-carrier (unfilled). A separate panel shows the coefficient of inbreeding calculation for first cousins (F = 1/16) with the path of identity by descent traced through the common grandparents. Hardy-Weinberg equations are shown alongside: q^2 = disease frequency, 2pq = carrier frequency.</image>

<image>A comparative infographic showing the evolution of carrier screening strategies from left to right. Panel 1 (1970s): ethnicity-targeted screening showing Tay-Sachs screening in a specific population. Panel 2 (2001): panethnic CF screening recommended for all couples. Panel 3 (2020s): expanded carrier screening panels showing a grid of 200+ conditions. Each panel includes approximate number of conditions screened, target population, and method used (enzyme assay, genotyping, NGS). A graph below shows detection rate across different ancestry groups, illustrating higher detection in well-studied populations and lower in underrepresented groups.</image>

<image>A residual risk calculation diagram for cystic fibrosis carrier screening. A Bayesian table format shows the prior carrier risk (1/25 for Northern European ancestry), the sensitivity of the screening panel (90% detection rate), and the calculated posterior (residual) risk after a negative screen result (approximately 1/240). A second example shows the same calculation for a different ancestry group with lower detection rate (e.g., 50% for Asian ancestry), yielding a higher residual risk. Color-coded bars visualize the magnitude of risk reduction.</image>

Clinical Pearls

The carrier frequency for autosomal recessive conditions can be estimated from disease prevalence using Hardy-Weinberg equilibrium: carrier frequency is approximately 2 times the square root of disease prevalence. Consanguineous couples should be offered expanded carrier screening, and exome or genome sequencing should be considered if offspring have unexplained developmental concerns, given the high probability of a rare recessive condition. Runs of homozygosity on SNP microarray can reveal unsuspected consanguinity and serve as a red flag for autosomal recessive conditions in the homozygous intervals. Carrier screening panels vary significantly between laboratories in gene content and detection rates, and clinicians should understand the panel composition and limitations of the platform they order. A negative expanded carrier screening result does not make a couple "low risk" for having a child with a genetic condition; it reduces the risk for conditions on the panel but does not address de novo dominant, X-linked, or non-screened recessive conditions. Pseudodeficiency alleles can cause false-positive results on enzyme-based carrier screening (such as for Tay-Sachs), and molecular confirmation should be reflexed when enzyme activity is low. SMA carrier screening requires copy number analysis of SMN1, as standard sequencing cannot detect the common deletion, and 2+0 carrier genotypes (two copies of SMN1 on one chromosome) can yield false-negative results, particularly in individuals of African descent.

References

• Gregg AR et al. Screening for autosomal recessive and X-linked conditions during pregnancy and preconception: a practice resource of the ACMG. Genet Med. 2021;23(10):1793-1806.
• Henneman L et al. Responsible implementation of expanded carrier screening. Eur J Hum Genet. 2016;24(6):e1-e12.
• Lazarin GA et al. An empirical estimate of carrier frequencies for 400+ causal Mendelian variants. Genet Med. 2013;15(3):178-186.
• Committee on Genetics, ACOG. Carrier screening for genetic conditions. Committee Opinion No. 691. 2017 (reaffirmed 2023).
• Antonarakis SE. Carrier screening for recessive disorders. Nat Rev Genet. 2019;20(9):549-561.

Read this lecture as Markdown